BETA AMYLOID POLYCLONAL ANTIBODY IMMUNOGENICITY AS EARLY DEVELOPMENT STUDY OF EARLY DIAGNOSIS FOR ALZHEIMER’S DISEASE

Authors

  • Muhamad Rasjad Indra Laboratorium Fisiologi Fakultas Kedokteran Universitas Brawijaya, Malang
  • Eko Arisetijono Marhaendraputro Laboratorium Neurologi Fakultas Kedokteran Universitas Brawijaya, Malang
  • Rudi Rakhmad Hidayat Program Studi Pendidikan Dokter Fakultas Kedokteran Universitas Brawijaya, Malang

Keywords:

Alzheimer's disease, antibodies, beta amyloid

Abstract

Background. Alzheimer's disease is a progressive neurologic disease of the brain that triggers irreversible neuronal cell loss, which can interfere with social and occupational functioning. The theory of ACH (Amyloid Cascade Hypothesis) states there are deposits and misfolding of beta amyloid protein thus lead to the formation of plaques and tangles in neurons cells.
Objective. To identify the immunogenicity of beta amyloid polyclonal antibodies that can be developed as a first step early diagnosis of Alzheimer's disease.
Methods. Rrandomized group post test only design conducted on rabbits. Blood samples were taken from rabbits that had been injected antigen once a week for 5 weeks. Variables were found in this study is the formation of beta amyloid polyclonal antibody with detection levels using dot blot and ELISA methods.
Results. It has been reproduced specific polyclonal antibody beta amyloid which has been evidenced by the bond between the antigen with the antibody in a dot blot.
Conclusion. The beta amyloid antibodies can be produced through production techniques with a polyclonal antibody against beta amyloid antigen induced rabbit.

References

Berchtold NC, Cotman CW. Evolution in the conceptualization of dementia and Alzheimer's disease: Greco-Roman period to the 1960s. Neurobiol. Aging. 2008;19(3):173–89.

Lahiri DK, Maloney B. "Beyond the signaling effect role of amyloid–β42 on the processing of AβPP, and its clinical implications". Exp. Neurol. 2010;225 (1): 51–4.

Brookmeyer R, Johnson E, Ziegler-Graham K, MH Arrighi. Forecasting the global burden of Alzheimer's disease. Alzheimer's and Dementia. 2007 [cited 2008-06-18];3(3):186–91.

G. Glenner and C. W. Wong, “Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein,†Biochemical and Biophysical Research Communications, 2004, vol. 122, no. 3, pp.1131–1135.

Abbas AK, Licthman AH. Basic Immunology edisi 3. Saunders. 2010.

Anoop, A., Pradeep K. Singh., Reeba S. Jacob., and Samir K. Maji. CSF Biomarkers for Alzheimer's Disease Diagnosis. Int J Alzheimer Dis. 2010; 2010: 606802. Published online Jun 23, 2010. doi: 10.4061/2010/606802. PMCID:PMC291579.

Downloads

Published

2017-01-01

How to Cite

Indra, M. R., Marhaendraputro, E. A., & Hidayat, R. R. (2017). BETA AMYLOID POLYCLONAL ANTIBODY IMMUNOGENICITY AS EARLY DEVELOPMENT STUDY OF EARLY DIAGNOSIS FOR ALZHEIMER’S DISEASE. MNJ (Malang Neurology Journal), 3(1), 1–4. Retrieved from https://mnj.ub.ac.id/index.php/mnj/article/view/243

Issue

Section

Research Article